Biomaxx
Semper sursum
- Joined
- Oct 12, 2025
- Posts
- 3,777
- Reputation
- 8,524
could LOXO-435 be the best option for fgfr3 inhibtion ?
Patented by LILLY, LOXO-435 is a highly selective FGFR3 inhibitor
If you are unsure of what fgfr3 does-
https://looksmax.gg/threads/fgfr3-inhibtion-epiphyseal-plates-and-bone-growth.19180/
LOXO-435 is confined to oncologic trials, no pediatric or skeletal growth studies have been initiated.
comparisons
Patented by LILLY, LOXO-435 is a highly selective FGFR3 inhibitor
If you are unsure of what fgfr3 does-
https://looksmax.gg/threads/fgfr3-inhibtion-epiphyseal-plates-and-bone-growth.19180/
LOXO-435 is confined to oncologic trials, no pediatric or skeletal growth studies have been initiated.
comparisons
Safety. Sides. Efficacy.
| LOXO | high | very low | high |
| VORS | high | near to none | mid |
| ERDA | low | very high | high |
| INFI | mid | mid | high |
Loxo-435
LOXO-435 is the most selective inhibitor studied to date. 361-fold selectivity over FGFR1 and 66-fold over FGFR2 .
This matters because pan-FGFR inhibitors (erdafitinib, infigratinib) hit FGFR1/2/4 and cause body wide toxicities, skin disorders, phosphatemia and more.
Unlike vosoritide and meclozine, which act indirectly via the CNP/cGMP pathway or analogous pathways, LOXO-435, as a direct small molecule inhibitor of the FGFR3 kinase, binds the receptor directly.
(Its direct)
Loxo is oral and taken twice a day (once may be adequate for plates). Around 100mg a day. Theoretically a 2 month onset
Loxo imo, a very promising inhibitor
Highly effective
Highly selective
Direct
Cheap
But long onset
Studies
https://share.google/upuke5VGU4FyoD2bl
https://share.google/skUVinxfXwPurjQmt
https://aacrjournals.org/mct/articl...scovery-of-a-highly-potent-and?sharetype=link
Short thread ik
Yall think ive stepped up my content recently ?
biomaxx





